by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
Advancements in basic science and successful clinical trials have provided the foundation for the rapid expansion of treatment options for multiple......READ MORE
by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
From B-cell–depleting monoclonal antibodies to sphingosine-1-phosphate receptor modulators, the diversity of the available high-potency therapies i......READ MORE
by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
The expansion of the multiple sclerosis (MS) treatment arsenal has led to more options for disease-modifying therapy (DMT) than ever before. Althou......READ MORE
by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
Additional disease-modifying therapies (DMTs) allow for greater flexibility in considering agents that vary in mechanism of action and route of adm......READ MORE
by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Highly effective anti-inflammatory therapies are available for treating patients with relapsing-remitting multiple sclerosis (MS). The disease star......READ MORE
